Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Chronic Heart Failure

Free Subscription Articles published in J Mol Cell Cardiol Retrieve available abstracts of 42 articles: HTML format

Single Articles

April 2025
1. SPAGNOL G, Trease A, Zheng L, Sobota S, et al
   Cx45 regulation by kinases and impact of expression in heart failure.
   J Mol Cell Cardiol. 2025;203:91-105.
   PubMed     Abstract available
   
   
   
2. MCLENDON JM, Zhang X, Stein CS, Baehr LM, et al
   Gain and loss of the centrosomal protein taxilin-beta influences cardiac proteostasis and stress.
   J Mol Cell Cardiol. 2025;201:56-69.
   PubMed     Abstract available
   
   
   
3. SMOLGOVSKY S, Bayer AL, Aronovitz M, Vanni KMM, et al
   Experimental pressure overload induces a cardiac neoantigen specific humoral immune response.
   J Mol Cell Cardiol. 2025;201:87-93.
   PubMed     Abstract available
   
   
   March 2025
4. ROBERTS TD, Hutchinson DS, Wootten D, De Blasio MJ, et al
   Advances in incretin therapies for targeting cardiovascular disease in diabetes.
   J Mol Cell Cardiol. 2025;202:102-115.
   PubMed     Abstract available
   
   
   
5. CHEN Z, Zhong M, Lin Y, Zhang W, et al
   METTL7B-induced histone lactylation prevents heart failure by ameliorating cardiac remodelling.
   J Mol Cell Cardiol. 2025 Mar 9:S0022-2828(25)00046.
   PubMed     Abstract available
   
   
   February 2025
6. GUAN J, Fefelova N, Zhai P, Ikeda Y, et al
   Dual inhibition of Mst1 and Mst2 exacerbates cardiac dysfunction during pressure overload stress in mice.
   J Mol Cell Cardiol. 2025;199:133-136.
   PubMed     Abstract available
   
   
   January 2025
7. SHABANI P, Dong F, Yun J, Shin SY, et al
   Does coronary microvascular dysfunction play a role in heart failure with reduced ejection fraction?
   J Mol Cell Cardiol. 2025 Jan 28:S0022-2828(25)00007.
   PubMed     Abstract available
   
   
   December 2024
8. KASS DA
   Assessing and interpreting diastolic function in animal models of heart disease.
   J Mol Cell Cardiol. 2024;197:1-4.
   PubMed     Abstract available
   
   
   November 2024
9. KATTIH B, Fischer A, Muhly-Reinholz M, Tombor L, et al
   Inhibition of miR-92a normalizes vascular gene expression and prevents diastolic dysfunction in heart failure with preserved ejection fraction.
   J Mol Cell Cardiol. 2024 Nov 24:S0022-2828(24)00194.
   PubMed     Abstract available
   
   
   
10. FU J, Li L, Chen L, Su C, et al
    Corrigendum to "PGE2 protects against heart failure through inhibiting TGF-beta1 synthesis in cardiomyocytes and crosstalk between TGF-beta1 and GRK2" [Journal of Molecular and Cellular Cardiology. 172(2022) 63-77].
    J Mol Cell Cardiol. 2024 Nov 22:S0022-2828(24)00191.
    PubMed    
    
    
    
11. ABBAS N, Bentele M, Waleczek FJG, Fuchs M, et al
    Ex vivo modelling of cardiac injury identifies ferroptosis-related pathways as a potential therapeutic avenue for translational medicine.
    J Mol Cell Cardiol. 2024;196:125-140.
    PubMed     Abstract available
    
    
    
12. ZERVOU S, McAndrew DJ, Lake HA, Kuznecova E, et al
    Cardiac function and energetics in mice with combined genetic augmentation of creatine and creatine kinase activity.
    J Mol Cell Cardiol. 2024;196:105-114.
    PubMed     Abstract available
    
    
    October 2024
13. JANI VP, Koleini N, Fenwick AJ, Sharp TE, et al
    Cardiomyocyte myofilament function in common animal models of heart failure with preserved ejection fraction.
    J Mol Cell Cardiol. 2024 Oct 18:S0022-2828(24)00166.
    PubMed     Abstract available
    
    
    
14. BEITO M, Taegtmeyer H
    Metabolic cycles: A unifying concept for energy transfer in the heart.
    J Mol Cell Cardiol. 2024;195:103-109.
    PubMed     Abstract available
    
    
    
15. FAN D, Wu R
    Mechanisms of the septic heart: From inflammatory response to myocardial edema.
    J Mol Cell Cardiol. 2024;195:73-82.
    PubMed     Abstract available
    
    
    
16. KAPLAN AD, Boyman L, Ward CW, Lederer WJ, et al
    Ryanodine receptor stabilization therapy suppresses Ca(2+)- based arrhythmias in a novel model of metabolic HFpEF.
    J Mol Cell Cardiol. 2024;195:68-72.
    PubMed     Abstract available
    
    
    August 2024
17. WALKER MA, Tian R
    NAD metabolism and heart failure: Mechanisms and therapeutic potentials.
    J Mol Cell Cardiol. 2024;195:45-54.
    PubMed     Abstract available
    
    
    July 2024
18. CANTRELL AC, Besanson J, Williams Q, Hoang N, et al
    Ferrostatin-1 specifically targets mitochondrial iron-sulfur clusters and aconitase to improve cardiac function in Sirtuin 3 cardiomyocyte knockout mice.
    J Mol Cell Cardiol. 2024;192:36-47.
    PubMed     Abstract available
    
    
    
19. LAHIRI SK, Lu J, Aguilar-Sanchez Y, Li H, et al
    Targeting Calpain-2-mediated Junctophilin-2 cleavage delays heart failure progression following myocardial infarction.
    J Mol Cell Cardiol. 2024 Jul 1:S0022-2828(24)00108.
    PubMed     Abstract available
    
    
    April 2024
20. CHOKSEY A, Carter RD, Thackray BD, Ball V, et al
    AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats.
    J Mol Cell Cardiol. 2024;191:12-22.
    PubMed     Abstract available
    
    
    March 2024
21. NGUYEN T, Rosa-Garrido M, Sadek H, Garry DJ, et al
    Promoting cardiomyocyte proliferation for myocardial regeneration in large mammals.
    J Mol Cell Cardiol. 2024;188:52-60.
    PubMed     Abstract available
    
    
    February 2024
22. ANTIPENKO S, Mayfield N, Jinno M, Gunzer M, et al
    Neutrophils are indispensable for adverse cardiac remodeling in heart failure.
    J Mol Cell Cardiol. 2024;189:1-11.
    PubMed     Abstract available
    
    
    
23. SOMA Y, Tani H, Morita-Umei Y, Kishino Y, et al
    Pluripotent stem cell-based cardiac regenerative therapy for heart failure.
    J Mol Cell Cardiol. 2024;187:90-100.
    PubMed     Abstract available
    
    
    
24. SAKAMOTO T, Kelly DP
    Cardiac maturation.
    J Mol Cell Cardiol. 2024;187:38-50.
    PubMed     Abstract available
    
    
    January 2024
25. SHI L, Li X, Zhang M, Qin C, et al
    Downregulation of Wtap causes dilated cardiomyopathy and heart failure.
    J Mol Cell Cardiol. 2024 Jan 13:S0022-2828(24)00002.
    PubMed     Abstract available
    
    
    
26. SHINTANI Y, Fukushima S, Varela-Carver A, Lee J, et al
    Corrigendum to "Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure" [J Mol Cell Cardiol 47 (2009) 288-295].
    J Mol Cell Cardiol. 2024 Jan 10:S0022-2828(24)00001.
    PubMed    
    
    
    
27. CHU Y, Hua Y, He L, He J, et al
    beta-hydroxybutyrate administered at reperfusion reduces infarct size and preserves cardiac function by improving mitochondrial function through autophagy in male mice.
    J Mol Cell Cardiol. 2024;186:31-44.
    PubMed     Abstract available
    
    
    November 2023
28. MANGIONE MC, Wen J, Cao DJ
    Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases.
    J Mol Cell Cardiol. 2023;186:111-124.
    PubMed     Abstract available
    
    
    
29. CHEN S, Wang K, Wang J, Chen X, et al
    Profiling cardiomyocytes at single cell resolution reveals COX7B could be a potential target for attenuating heart failure in cardiac hypertrophy.
    J Mol Cell Cardiol. 2023;186:45-56.
    PubMed     Abstract available
    
    
    October 2023
30. WADDELL HMM, Mereacre V, Alvarado FJ, Munro ML, et al
    Clustering properties of the cardiac ryanodine receptor in health and heart failure.
    J Mol Cell Cardiol. 2023;185:38-49.
    PubMed     Abstract available
    
    
    
31. ZHAO C, Jiang X, Peng L, Zhang Y, et al
    Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
    J Mol Cell Cardiol. 2023;185:13-25.
    PubMed     Abstract available
    
    
    
32. MENASCHE P
    Human PSC-derived cardiac cells and their products: therapies for cardiac repair.
    J Mol Cell Cardiol. 2023;183:14-21.
    PubMed     Abstract available
    
    
    September 2023
33. LIU Z, Liu Z, Xu X, Zhou Y, et al
    Role of ventrolateral part of ventromedial hypothalamus in post-myocardial infarction cardiac dysfunction induced by sympathetic nervous system.
    J Mol Cell Cardiol. 2023 Sep 30:S0022-2828(23)00154.
    PubMed     Abstract available
    
    
    
34. PEZHOUMAN A, Nguyen NB, Kay M, Kanjilal B, et al
    Cardiac regeneration - Past advancements, current challenges, and future directions.
    J Mol Cell Cardiol. 2023;182:75-85.
    PubMed     Abstract available
    
    
    August 2023
35. KMIETCZYK V, Oelschlager J, Gupta P, Varma E, et al
    Ythdf2 regulates cardiac remodeling through its mRNA target transcripts.
    J Mol Cell Cardiol. 2023;181:57-66.
    PubMed     Abstract available
    
    
    July 2023
36. KOBAYASHI S, Yamamoto T, Yano M
    RyR2-stabilization therapy with dantrolene against left ventricular remodeling and lethal arrhythmia in heart failure.
    J Mol Cell Cardiol. 2023 Jul 5:S0022-2828(23)00108.
    PubMed    
    
    
    June 2023
37. MONTANES-AGUDO P, Pinto YM, Creemers EE
    Splicing factors in the heart: Uncovering shared and unique targets.
    J Mol Cell Cardiol. 2023;179:72-79.
    PubMed     Abstract available
    
    
    May 2023
38. YAMADA Y, Sadahiro T, Ieda M
    Development of direct cardiac reprogramming for clinical applications.
    J Mol Cell Cardiol. 2023;178:1-8.
    PubMed     Abstract available
    
    
    April 2023
39. MEHDIPOUR M, Park S, Huang GN
    Unlocking cardiomyocyte renewal potential for myocardial regeneration therapy.
    J Mol Cell Cardiol. 2023;177:9-20.
    PubMed     Abstract available
    
    
    
40. LI R, Xiang C, Li Y, Nie Y, et al
    Targeting immunoregulation for cardiac regeneration.
    J Mol Cell Cardiol. 2023;177:1-8.
    PubMed     Abstract available
    
    
    March 2023
41. GARRY GA, Olson EN
    Reprogramming of cardiac cell fate as a therapeutic strategy for ischemic heart disease.
    J Mol Cell Cardiol. 2023 Mar 28:S0022-2828(23)00058.
    PubMed     Abstract available
    
    
    
42. FUJII S, Kobayashi S, Chang Y, Nawata J, et al
    RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
    J Mol Cell Cardiol. 2023 Mar 22:S0022-2828(23)00052.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.